Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13226)
All Articles published online
|
Publishing Process of This Article
|
Apr 21, 2013 (publication date) through Feb 2, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol 2013; 19(15): 2298-2306 [PMID: 23613622 DOI: 10.3748/wjg.v19.i15.2298] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i15/2298.htm |
| Number | Citing Articles |
| 1 |
Ramesh Kumar, Diego García-Compeán, Tanmoy Maji. Hepatogenous diabetes: Knowledge, evidence, and skepticism. World Journal of Hepatology 2022; 14(7): 1291-1306 doi: 10.4254/wjh.v14.i7.1291
|
| 2 |
Masaru Harada, Akitoshi Yoneda, Sanehito Haruyama, Kei Yabuki, Yuichi Honma, Masaaki Hiura, Michihiko Shibata, Hidehiko Matsuoka, Yasuhiro Uchiwa. Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma. Internal Medicine 2017; 56(18): 2471 doi: 10.2169/internalmedicine.8703-16
|
| 3 |
T. S. Panevin. Effect of oral antihyperglycemic drugs on purine metabolism. Diabetes mellitus 2021; 24(4): 342 doi: 10.14341/DM12756
|
| 4 |
Xiaodan Zheng, Changchun Cao, Yongcheng He, Xinyu Wang, Jun Wu, Haofei Hu. Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. Lipids in Health and Disease 2021; 20(1) doi: 10.1186/s12944-021-01485-x
|
| 5 |
Shuling Ren, Daria Gaykalova, Jennifer Wang, Theresa Guo, Ludmila Danilova, Alexander Favorov, Elana Fertig, Justin Bishop, Zubair Khan, Emily Flam, Piotr T. Wysocki, Peter DeJong, Mizuo Ando, Chao Liu, Akihiro Sakai, Takahito Fukusumi, Sunny Haft, Sayed Sadat, Joseph A. Califano. Discovery and development of differentially methylated regions in human papillomavirus‐related oropharyngeal squamous cell carcinoma. International Journal of Cancer 2018; 143(10): 2425 doi: 10.1002/ijc.31778
|
| 6 |
Salwa H. Gomaa, Mona M. Abaza, Hoda A. Elattar, Gamal A. Amin, Doaa M. Elshahawy. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians. Arab Journal of Gastroenterology 2020; 21(4): 224 doi: 10.1016/j.ajg.2020.04.016
|
| 7 |
Hebatollah E. Eitah, Hanan Naeim Attia, Ahmed A.F. Soliman, Amina A. Gamal el Din, Khaled Mahmoud, Rabab H. Sayed, Yousreya A. Maklad, Ayman E. El-Sahar. Vitamin D ameliorates diethylnitrosamine-induced liver preneoplasia: A pivotal role of CYP3A4/CYP2E1 via DPP-4 enzyme inhibition. Toxicology and Applied Pharmacology 2023; 458: 116324 doi: 10.1016/j.taap.2022.116324
|
| 8 |
Yuichiro Amano, Shuntarou Tsuchiya, Mayumi Imai, Kimio Tohyama, Jun Matsukawa, Osamu Isono, Hironobu Yasuno, Kazuaki Enya, Emiko Koumura, Hiroshi Nagabukuro. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochemical and Biophysical Research Communications 2018; 497(1): 207 doi: 10.1016/j.bbrc.2018.02.055
|
| 9 |
Nagla A. El-Sherbeeny, Manar A. Nader. The protective effect of vildagliptin in chronic experimental cyclosporine A-induced hepatotoxicity. Canadian Journal of Physiology and Pharmacology 2016; 94(3): 251 doi: 10.1139/cjpp-2015-0336
|
| 10 |
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, Arun J. Sanyal. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes, Obesity and Metabolism 2021; 23(5): 1069 doi: 10.1111/dom.14322
|
| 11 |
Mandeep Kumar Singh, Bhrigu Kumar Das, Sandeep Choudhary, Deepak Gupta, Umesh K Patil. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomedicine & Pharmacotherapy 2018; 106: 991 doi: 10.1016/j.biopha.2018.06.095
|
| 12 |
Amélio F. Godoy-Matos, Wellington S. Silva Júnior, Cynthia M. Valerio. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & Metabolic Syndrome 2020; 12(1) doi: 10.1186/s13098-020-00570-y
|
| 13 |
Dan Kawamori, Jun Shirakawa, Chong Wee Liew, Jiang Hu, Tomoaki Morioka, Alokesh Duttaroy, Bryan Burkey, Rohit N. Kulkarni. GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice. Diabetologia 2017; 60(8): 1442 doi: 10.1007/s00125-017-4303-6
|
| 14 |
Ashwani Sharma, Tarun Virmani, Anjali Sharma, Vaishnavi Chhabra, Girish Kumar, Kamla Pathak, Abdulsalam Alhalmi. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2022; : 1845 doi: 10.2147/DMSO.S369712
|
| 15 |
Wang Xinhua, Qiu Xiangting, Chen Lingling, Li Guohong. Prognostic Significance of Serum CD26 Concentration in Patients with Esophageal Squamous Cell Carcinoma. Archives of Medical Research 2016; 47(4): 299 doi: 10.1016/j.arcmed.2016.07.005
|
| 16 |
Salma A. El-Marasy, Rehab F. Abdel-Rahman, Reham M. Abd-Elsalam. Neuroprotective effect of vildagliptin against cerebral ischemia in rats. Naunyn-Schmiedeberg's Archives of Pharmacology 2018; 391(10): 1133 doi: 10.1007/s00210-018-1537-x
|
| 17 |
Karolien Buyl, Tamara Vanhaecke, Terry Desmae, Laurence Lagneaux, Vera Rogiers, Mehdi Najar, Joery De Kock. Evaluation of a new standardized enzymatic isolation protocol for human umbilical cord-derived stem cells. Toxicology in Vitro 2015; 29(6): 1254 doi: 10.1016/j.tiv.2014.12.008
|
| 18 |
Xiaowei Xing, Shuang Guo, Yusheng Liu, Jiangying Kuang, Zhiwei Huang, Xin Wang, Qinghua Lu. Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP‑1‑dependent nephrocyte apoptosis. Experimental and Therapeutic Medicine 2021; 22(3) doi: 10.3892/etm.2021.10422
|
| 19 |
André J Scheen. A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 2015; 16(1): 43 doi: 10.1517/14656566.2015.978289
|
| 20 |
Mahmoud Khattab, Magdy Fouad, Elham Ahmed. Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World Journal of Hepatology 2015; 7(23): 2474-2481 doi: 10.4254/wjh.v7.i23.2474
|
| 21 |
Yi Wang, Xueli Wu, Yiyu Cheng, Xiaoping Zhao. A fluorescent switchable AIE probe for selective imaging of dipeptidyl peptidase-4 in vitro and in vivo and its application in screening DPP-4 inhibitors. Chemical Communications 2016; 52(17): 3478 doi: 10.1039/C5CC08921B
|
| 22 |
André J Scheen. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 2015; 14(4): 505 doi: 10.1517/14740338.2015.1006625
|
| 23 |
Nao Shigematsu, Takehiro Kawashiri, Daisuke Kobayashi, Shiori Shimizu, Keisuke Mine, Shiori Hiromoto, Mayako Uchida, Nobuaki Egashira, Takao Shimazoe. Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-62738-w
|
| 24 |
Tao Liu, Jing Ning, Bo Wang, Bin Dong, Song Li, Xiangge Tian, Zhenlong Yu, Yulin Peng, Chao Wang, Xinyu Zhao, Xiaokui Huo, Chengpeng Sun, Jingnan Cui, Lei Feng, Xiaochi Ma. Activatable Near-Infrared Fluorescent Probe for Dipeptidyl Peptidase IV and Its Bioimaging Applications in Living Cells and Animals. Analytical Chemistry 2018; 90(6): 3965 doi: 10.1021/acs.analchem.7b04957
|
| 25 |
Natasha A. Trzaskalski, Branka Vulesevic, My-Anh Nguyen, Natasha Jeraj, Evgenia Fadzeyeva, Nadya M. Morrow, Cassandra A.A. Locatelli, Nicole Travis, Antonio A. Hanson, Julia R.C. Nunes, Conor O’Dwyer, Jelske N. van der Veen, Ilka Lorenzen-Schmidt, Rick Seymour, Serena M. Pulente, Andrew C. Clément, Angela M. Crawley, René L. Jacobs, Mary-Anne Doyle, Curtis L. Cooper, Kyoung-Han Kim, Morgan D. Fullerton, Erin E. Mulvihill. Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression. JCI Insight 2023; 8(2) doi: 10.1172/jci.insight.154314
|
| 26 |
Ilaria Barchetta, Valentina Ceccarelli, Flavia A. Cimini, Eugenio Barone, Federica Sentinelli, Mariagrazia Coluzzi, Caterina Chiappetta, Laura Bertoccini, Antonella Tramutola, Giancarlo Labbadia, Claudio Di Cristofano, Gianfranco Silecchia, Frida Leonetti, Maria G. Cavallo. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. Journal of Endocrinological Investigation 2021; 44(5): 979 doi: 10.1007/s40618-020-01392-5
|
| 27 |
Tolulope Eniola Omolekulo, Olugbenga Samuel Michael, Lawrence Aderemi Olatunji. Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid. Biomedicine & Pharmacotherapy 2019; 110: 869 doi: 10.1016/j.biopha.2018.12.036
|
| 28 |
Shira Yair-Sabag, Elchanan Nussinson, Ofir Ben-Assuli, Fahmi Shibli, Azmi Shahbari, Shira Zelber-Sagi. Retrospective study of the associations between hepatitis C virus infection and metabolic factors. World Journal of Hepatology 2016; 8(30): 1269-1278 doi: 10.4254/wjh.v8.i30.1269
|
| 29 |
Tsukasa Kawaguchi, Takahiro Kodama, Hayato Hikita, Yuki Makino, Yoshinobu Saito, Satoshi Tanaka, Satoshi Shimizu, Ryotaro Sakamori, Takuya Miyagi, Hiroshi Wada, Hiroaki Nagano, Naoki Hiramatsu, Tomohide Tatsumi, Tetsuo Takehara. Synthetic lethal interaction of combined CD26 and Bcl‐xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma. Hepatology Research 2015; 45(9): 1023 doi: 10.1111/hepr.12434
|
| 30 |
Takumi Kawaguchi, Dan Nakano, Takuji Torimura. Alcoholic/Non-Alcoholic Digestive Diseases. 2019; : 65 doi: 10.1007/978-981-13-1465-0_7
|
| 31 |
Estefania Zapata-Bravo, Antonios Douros, Oriana Hoi Yun Yu, Kristian B. Filion. Comparative risk of infection of medications used for type 2 diabetes. Expert Opinion on Drug Safety 2024; 23(9): 1079 doi: 10.1080/14740338.2024.2401024
|
| 32 |
Lili Niu, Philipp E Geyer, Nicolai J Wewer Albrechtsen, Lise L Gluud, Alberto Santos, Sophia Doll, Peter V Treit, Jens J Holst, Filip K Knop, Tina Vilsbøll, Anders Junker, Stephan Sachs, Kerstin Stemmer, Timo D Müller, Matthias H Tschöp, Susanna M Hofmann, Matthias Mann. Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease. Molecular Systems Biology 2019; 15(3) doi: 10.15252/msb.20188793
|
| 33 |
Sanbao Chai, Shuqing Yu, Zhirong Yang, Shanshan Wu, Le Gao, Haining Wang, Yuan Zhang, Siyan Zhan, Linong Ji, Feng Sun. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. BMJ Open Diabetes Research & Care 2019; 7(1): e000728 doi: 10.1136/bmjdrc-2019-000728
|
| 34 |
Vittorio Bertone, Eleonora Tarantola, Isabel Freitas. Histochemistry of Single Molecules. Methods in Molecular Biology 2017; 1560: 45 doi: 10.1007/978-1-4939-6788-9_3
|
| 35 |
T. Zheng, A. Baskota, Y. Gao, H. Tian, F. Yang. Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. Nephrology Dialysis Transplantation 2015; 30(3): 460 doi: 10.1093/ndt/gfu312
|
| 36 |
E. Kutoh. Probable linagliptin-induced liver toxicity: A case report. Diabetes & Metabolism 2014; 40(1): 82 doi: 10.1016/j.diabet.2013.09.009
|
| 37 |
N. Nishii, S. Takashima, A. Iguchi, Y. Murahata, A. Matsuu, Y. Hikasa, H. Kitagawa. Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats. Domestic Animal Endocrinology 2014; 49: 14 doi: 10.1016/j.domaniend.2014.04.006
|
| 38 |
Hengning Ke, Rui Yuan, Huan Liu, Mingqi Luo, Hui Hu, Ejuan Zhang, Ke Zhuang, Yong Yang, Rongrong Yang. Serum protein biomarkers for HCC risk prediction in HIV/HBV co-infected people: a clinical proteomic study using mass spectrometry. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1282469
|
| 39 |
Ji Cheol Bae. DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?. Endocrinology and Metabolism 2022; 37(6): 858 doi: 10.3803/EnM.2022.605
|
| 40 |
Xin Wang, Jing Ke, Ying-jun Zhu, Bin Cao, Rui-li Yin, Yan Wang, Ling-ling Wei, Li-jie Zhang, Long-yan Yang, Dong Zhao. Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway. Cell Death Discovery 2021; 7(1) doi: 10.1038/s41420-021-00625-7
|
| 41 |
Minyoung Lee, Eugene Shin, Jaehyun Bae, Yongin Cho, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-75288-y
|
| 42 |
Chiao-Wei Lin, Ting-Wei Huang, Yu-Ju Peng, Yuan-Yu Lin, Harry John Mersmann, Shih-Torng Ding. A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets. Poultry Science 2021; 100(3): 100869 doi: 10.1016/j.psj.2020.11.046
|
| 43 |
Kerstin Rufinatscha, Bernhard Radlinger, Jochen Dobner, Sabrina Folie, Claudia Bon, Elisabeth Profanter, Claudia Ress, Karin Salzmann, Gabriele Staudacher, Herbert Tilg, Susanne Kaser. Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes. Biochemical and Biophysical Research Communications 2017; 485(2): 366 doi: 10.1016/j.bbrc.2017.02.071
|
| 44 |
Vivek Bora, Bhoomika M. Patel. Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer. Life Sciences 2021; 274: 119329 doi: 10.1016/j.lfs.2021.119329
|
| 45 |
Takumi Kawaguchi, Dan Nakano, Hironori Koga, Takuji Torimura. Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model. Liver Cancer 2019; 8(5): 359 doi: 10.1159/000491763
|
| 46 |
A.J. Scheen. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes & Metabolism 2019; 45(3): 213 doi: 10.1016/j.diabet.2019.01.008
|
| 47 |
Yosra M. Magdy, Omnyah A. El-Kharashi, Enas S. Nabih, Safaa M. Shaker, Lobna F. Abd-Elaziz, Sawsan Aboul-Fotouh. Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. Biomedicine & Pharmacotherapy 2017; 85: 225 doi: 10.1016/j.biopha.2016.10.098
|
| 48 |
Shoji Takagi, Mitsuyoshi Hirokawa, Kenji Nagashima, Miyoko Higuchi, Kyuichi Kadota, Ryou Ishikawa, Masakazu Sato, Akira Miyauchi, Yasuyuki Miyake, Reiji Haba. Diagnostic significance of apical membranous and cytoplasmic dot-like CD26 expression in encapsulated follicular variant of papillary thyroid carcinoma: a useful marker for capsular invasion. Endocrine Journal 2020; 67(12): 1207 doi: 10.1507/endocrj.EJ19-0501
|
| 49 |
Shahid Ali, Sibhghatulla Shaikh, Khurshid Ahmad, Inho Choi. Identification of active compounds as novel dipeptidyl peptidase-4 inhibitors through machine learning and structure-based molecular docking simulations. Journal of Biomolecular Structure and Dynamics 2025; 43(4): 1611 doi: 10.1080/07391102.2023.2292299
|
| 50 |
Takuya Imatoh, Takumi Nishi, Midori Yasui, Toshiki Maeda, Kimie Sai, Yoshiro Saito, Hiroshi Une, Akira Babazono. Association between dipeptidyl peptidase‐4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study. Pharmacoepidemiology and Drug Safety 2018; 27(8): 931 doi: 10.1002/pds.4560
|
| 51 |
T Zheng, T Chen, Y Liu, Y Gao, H Tian. Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress. Journal of Human Hypertension 2015; 29(7): 424 doi: 10.1038/jhh.2014.111
|
| 52 |
Hao Yu, Xiao-Ping Mei, Peng-Fei Su, Guang-Zhi Jin, Hong-Kun Zhou. A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4. Brazilian Journal of Medical and Biological Research 2020; 53(4) doi: 10.1590/1414-431x20209114
|
| 53 |
Lindsey Wang, Nathan A. Berger, David C. Kaelber, Rong Xu. Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes. Gastroenterology 2024; 167(4): 689 doi: 10.1053/j.gastro.2024.04.029
|
| 54 |
Muhammed A. Saad, Alyasaa A. Rastanawi, Muhammed F. El-Yamany. Alogliptin abates memory injuries of hepatic encephalopathy induced by acute paracetamol intoxication via switching-off autophagy-related apoptosis. Life Sciences 2018; 215: 11 doi: 10.1016/j.lfs.2018.10.069
|
| 55 |
Yu Koyanagi, Takeshi Kawasaki, Yoshitoshi Kasuya, Ryo Hatano, Shun Sato, Yukiko Takahashi, Kei Ohnuma, Chikao Morimoto, Steven M. Dudek, Koichiro Tatsumi, Takuji Suzuki. Functional roles of CD26/DPP4 in bleomycin‐induced pulmonary fibrosis. Physiological Reports 2023; 11(6) doi: 10.14814/phy2.15645
|
| 56 |
Manar A. Nader. Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma. International Immunopharmacology 2015; 29(2): 761 doi: 10.1016/j.intimp.2015.08.043
|
| 57 |
Jane Rhyu, Run Yu. Newly discovered endocrine functions of the liver. World Journal of Hepatology 2021; 13(11): 1611-1628 doi: 10.4254/wjh.v13.i11.1611
|
| 58 |
Matteo Cerquetella, Sara Mangiaterra, Francesco Pinnella, Giacomo Rossi, Andrea Marchegiani, Alessandra Gavazza, Evelina Serri, Alessandro Di Cerbo, Carlotta Marini, Daniela Cecconi, Daniela Sorio, Veronica Marchetti, Silvia Vincenzetti. Fecal Proteome Profile in Dogs Suffering from Different Hepatobiliary Disorders and Comparison with Controls. Animals 2023; 13(14): 2343 doi: 10.3390/ani13142343
|
| 59 |
Yarini Arrebola Sánchez, Fabiola Almeida García, Daniel Ojeda del Sol, Mario E. Valdés-Tresanco, Carlos David Ortiz, Belinda Sánchez Ramírez, Isel Pascual Alonso. Dipeptidyl peptidase IV: a multifunctional enzyme with implications in several pathologies including cancer. Physical Sciences Reviews 2024; 9(8): 2541 doi: 10.1515/psr-2022-0288
|
| 60 |
Florian Gunnar Scurt, Katrin Bose, Ali Canbay, Peter R Mertens, Christos Chatzikyrkou. Ursachen der chronischen Nierenschädigung in Patienten mit Lebererkrankungen – Pathophysiologie und Therapiemöglichkeiten. Zeitschrift für Gastroenterologie 2021; 59(06): 560 doi: 10.1055/a-1402-1502
|
| 61 |
Osama A. Mohammed. Alogliptin exhibits multifaceted effects in thioacetamide-insulted rats: A novel approach to combating hepatic inflammation and fibrogenesis. Pathology - Research and Practice 2023; 250: 154833 doi: 10.1016/j.prp.2023.154833
|
| 62 |
Zeynep Mine Coskun, Meral Koyuturk, Sezin Karabulut, Sema Bolkent. CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin. Pharmacological Reports 2017; 69(4): 822 doi: 10.1016/j.pharep.2017.03.013
|
| 63 |
Takeshi Kawasaki, Weiguo Chen, Yu Maw Htwe, Koichiro Tatsumi, Steven M. Dudek. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. American Journal of Physiology-Lung Cellular and Molecular Physiology 2018; 315(5): L834 doi: 10.1152/ajplung.00031.2018
|
| 64 |
André J Scheen. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opinion on Drug Metabolism & Toxicology 2014; 10(6): 839 doi: 10.1517/17425255.2014.902444
|
| 65 |
Kathryn H. Williams, Ana Júlia Vieira De Ribeiro, Emilia Prakoso, Anne‐Sophie Veillard, Nicholas A. Shackel, Belinda Brooks, Yangmin Bu, Erika Cavanagh, Jim Raleigh, Susan V. McLennan, Geoffrey W. McCaughan, Fiona M. Keane, Amany Zekry, Mark D. Gorrell, Stephen M. Twigg. Circulating dipeptidyl peptidase‐4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non‐alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross‐sectional study. Journal of Diabetes 2015; 7(6): 809 doi: 10.1111/1753-0407.12237
|
| 66 |
James M. Henderson, Michelle S. W. Xiang, Jiali Carrie Huang, Stefanie Wetzel, Linxuan Jiang, Jack H. Lai, Wengen Wu, James G. Kench, William W. Bachovchin, Ben Roediger, Geoffrey W. McCaughan, Hui Emma Zhang, Mark D. Gorrell. Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. Cancers 2021; 13(21): 5495 doi: 10.3390/cancers13215495
|
| 67 |
Mirjam E. van Albada, Pratik Shah, Terry G. J. Derks, Sabine Fuchs, Judith J. M. Jans, Valérie McLin, Hubert P. J. van der Doef. Abnormal glucose homeostasis and fasting intolerance in patients with congenital porto-systemic shunts. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1190473
|
| 68 |
Giang Nguyen, So Young Park, Dinh Vinh Do, Dae-Hee Choi, Eun-Hee Cho. Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction. Endocrinology and Metabolism 2022; 37(6): 918 doi: 10.3803/EnM.2022.1530
|
| 69 |
Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Petta. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals 2018; 11(4): 121 doi: 10.3390/ph11040121
|
| 70 |
Kristina Kovacovicova, Manlio Vinciguerra. Inhibition of dipeptidyl peptidase 4 (DPP4) activates immune cells chemotaxis in hepatocellular carcinoma. Oncology Signaling 2019; 2: 1 doi: 10.1016/j.onsig.2019.08.001
|
| 71 |
S. V. Michurina, M. A. Cherepanova, I. Yu. Ishchenko, S. A. Arkhipov, V. V. Klimontov, E. L. Zav’yalov. Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice. Bulletin of Experimental Biology and Medicine 2019; 167(2): 210 doi: 10.1007/s10517-019-04493-1
|
| 72 |
Xiaoqing Ma, Wenhua Du, Shanshan Shao, Chunxiao Yu, Lingyan Zhou, Fei Jing. Vildagliptin Can Alleviate Endoplasmic Reticulum Stress in the Liver Induced by a High Fat Diet. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/5045182
|
| 73 |
Valeria Grancini, Veronica Resi, Eva Palmieri, Giuseppe Pugliese, Emanuela Orsi. Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacological Research 2019; 141: 556 doi: 10.1016/j.phrs.2019.01.042
|
| 74 |
Maryam Bayanati, Mohammad Ismail Mahboubi Rabbani, Shirin Sirous Kabiri, Bahareh Mir, Elham Rezaee, Sayyed Abbas Tabatabai. Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies. Iranian Journal of Pharmaceutical Research 2024; 23(1) doi: 10.5812/ijpr-151581
|
| 75 |
Tianpeng Zheng, Attit Baskota, Yun Gao, Tao Chen, Haoming Tian, Fan Yang. Increased plasma DPP4 activities predict new-onset hyperglycemia in Chinese over a four-year period: Possible associations with inflammation. Metabolism 2015; 64(4): 498 doi: 10.1016/j.metabol.2014.12.004
|
| 76 |
Jonathan M. Hazlehurst, Jeremy W. Tomlinson. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease. 2016; : 209 doi: 10.1002/9781118924938.ch24
|
| 77 |
Yoshinobu Nakamaru, Fumihiko Akahoshi, Hiroaki Iijima, Noriko Hisanaga, Toshiyuki Kume. Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors. Biopharmaceutics & Drug Disposition 2016; 37(3): 142 doi: 10.1002/bdd.2003
|
| 78 |
Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi, Theodoros Androutsakos. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. European Journal of Clinical Pharmacology 2024; 80(1): 127 doi: 10.1007/s00228-023-03586-1
|
| 79 |
Hanyan Zhang, Dandan Sun, Guanzhen Wang, Shichao Cui, Robert A. Field, Jia Li, Yi Zang. Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell. Biochemical and Biophysical Research Communications 2019; 511(2): 387 doi: 10.1016/j.bbrc.2019.02.065
|
| 80 |
Preetam Nath, Anil C. Anand. Hepatogenous Diabetes: A Primer. Journal of Clinical and Experimental Hepatology 2021; 11(5): 603 doi: 10.1016/j.jceh.2021.04.012
|
| 81 |
Ilaria Barchetta, Flavia Agata Cimini, Sara Dule, Maria Gisella Cavallo. Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis. Biomedicines 2022; 10(9): 2306 doi: 10.3390/biomedicines10092306
|
| 82 |
Yu-peng Li, Jing Xiao, Xu Liang, Yu Pei, Xiao-fei Han, Chen-xi Li, Hui Tian. DPP-4 inhibition resembles exercise in preventing type 2 diabetes development by inhibiting hepatic protein kinase Cε expression in a mouse model of hyperinsulinemia. Journal of International Medical Research 2020; 48(6) doi: 10.1177/0300060520934635
|
| 83 |
Chin-Hsiao Tseng, Kuo-Yang Lee, Farn-Hsuan Tseng. An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C 2015; 33(1): 67 doi: 10.1080/10590501.2015.1003496
|
| 84 |
Saeko Osawa, Dan Kawamori, Naoto Katakami, Mitsuyoshi Takahara, Fumie Sakamoto, Takashi Katsura, Tetsuyuki Yasuda, Hideaki Kaneto, Munehide Matsuhisa, Taka-aki Matsuoka, Iichiro Shimomura. Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes. Diabetes Research and Clinical Practice 2016; 113: 135 doi: 10.1016/j.diabres.2015.12.022
|
| 85 |
Tian Shen, Bilin Xu, Tao Lei, Lin Chen, Cuiping Zhang, Zhenhua Ni. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6554
|
| 86 |
Fereshteh Pashayee-khamene, Behzad Hatami, Makan Cheraghpour, Zahra Yari. Keeping an eye on the nutrition: The importance of nutrition management on cardiometabolic risk factors in cirrhotic patients. Clinical Nutrition ESPEN 2023; 58: 186 doi: 10.1016/j.clnesp.2023.09.927
|
| 87 |
Loris Zamai. Upregulation of the Renin–Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients. Cells 2021; 10(3): 506 doi: 10.3390/cells10030506
|
| 88 |
Mona M. Allam, Reham M. Ibrahim, Walaa Bayoumie El Gazzar, Mona A. Said. Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease. Archives of Physiology and Biochemistry 2024; 130(1): 87 doi: 10.1080/13813455.2021.1975758
|
| 89 |
Yan Zhang, Xiangyu Zhang, V. Wee Yong, Mengzhou Xue. Vildagliptin improves neurological function by inhibiting apoptosis and ferroptosis following intracerebral hemorrhage in mice. Neuroscience Letters 2022; 776: 136579 doi: 10.1016/j.neulet.2022.136579
|
| 90 |
TAKUMI ONOYAMA, MASAHIKO KODA, TOSHIAKI OKAMOTO, MANABU KISHINA, TOMOMITSU MATONO, TAKAAKI SUGIHARA, YOSHIKAZU MURAWAKI. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice. Molecular Medicine Reports 2015; 12(5): 6895 doi: 10.3892/mmr.2015.4329
|
| 91 |
Safwat A. Mangoura, Marwa A. Ahmed, Nashwa Hamad, Andrew Z. Zaka, Khaled A. Khalaf. Hepatoprotective effects of vildagliptin mitigates lung biochemical and histopathological changes in experimental hepatopulmonary syndrome model in rat. International Immunopharmacology 2024; 143: 113254 doi: 10.1016/j.intimp.2024.113254
|
| 92 |
Pankaj Puri, Narendra Kotwal. An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. Journal of Clinical and Experimental Hepatology 2022; 12(2): 560 doi: 10.1016/j.jceh.2021.09.010
|
| 93 |
Xun Cao, Xiao Zhou, Xiao-Min Liu, Li-Hong Zhou. Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats. Journal of Molecular Endocrinology 2016; 57(1): 13 doi: 10.1530/JME-16-0001
|
| 94 |
T.P. Zheng, F. Yang, Y. Gao, A. Baskota, T. Chen, H.M. Tian, X.W. Ran. Increased plasma DPP4 activities predict new-onset atherosclerosis in association with its proinflammatory effects in Chinese over a four year period: A prospective study. Atherosclerosis 2014; 235(2): 619 doi: 10.1016/j.atherosclerosis.2014.05.956
|
| 95 |
Shivani Srivastava, Durgavati Yadav, Yamini Bhusan Tripathi. DPP-IV Inhibitory Potential of Methanolic Extract of Pueraria Tuberosa in Liver of Alloxan Induced Diabetic Model. Biosciences Biotechnology Research Asia 2018; 15(1): 01 doi: 10.13005/bbra/2602
|
| 96 |
Rajeev K. Singla, Bairong Shen. In Silico ADMET Evaluation of Natural DPP-IV Inhibitors for Rational Drug Design against Diabetes. Current Drug Metabolism 2020; 21(10): 768 doi: 10.2174/1389200221999200901202945
|
| 97 |
Tongzhi Wu, Sony S. Thazhath, Michelle J. Bound, Karen L. Jones, Michael Horowitz, Christopher K. Rayner. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?. Diabetes Research and Clinical Practice 2014; 106(1): e3 doi: 10.1016/j.diabres.2014.08.004
|
| 98 |
Emanuela Orsi, Valeria Grancini, Stefano Menini, Alessio Aghemo, Giuseppe Pugliese. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?. Liver International 2017; 37(7): 950 doi: 10.1111/liv.13337
|
| 99 |
Hui Zhang, Sadiqa Maqsudi, Adam Rainczuk, Nadine Duffield, Josie Lawrence, Fiona M. Keane, Daniela Justa‐Schuch, Ruth Geiss‐Friedlander, Mark D. Gorrell, Andrew N. Stephens. Identification of novel dipeptidyl peptidase 9 substrates by two‐dimensional differential in‐gel electrophoresis. The FEBS Journal 2015; 282(19): 3737 doi: 10.1111/febs.13371
|
| 100 |
Zhihui Zhang, Ru Sun, Chong Bian, Hongbo Wang, Zhen Zhao, Panpan Lv, Jianzhong Lu, Haixin Zhang, Hulie Zeng, Yuanyuan Chen, Zhijuan Cao. A dual-protease-triggered chemiluminescent probe for precise tumor imaging. Chinese Chemical Letters 2025; 36(2): 109784 doi: 10.1016/j.cclet.2024.109784
|
| 101 |
Yukiko Takahashi, Takeshi Kawasaki, Hironori Sato, Yoshinori Hasegawa, Steven M. Dudek, Osamu Ohara, Koichiro Tatsumi, Takuji Suzuki. Functional Roles for CD26/DPP4 in Mediating Inflammatory Responses of Pulmonary Vascular Endothelial Cells. Cells 2021; 10(12): 3508 doi: 10.3390/cells10123508
|
| 102 |
Lin Chen, Xiujuan Zhang, Li Zhang, Dongmei Zheng. <p>Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020; : 3507 doi: 10.2147/DMSO.S262284
|
| 103 |
Jayjeet Majumdar, Aniruddha Chatterjee, Suman Bhusan Chakraborty, Pratip Chakraborty, Supriti Sarkar. Comparative efficacy of four potent bioactive molecules of fenugreek seed in holistic management of type 1 diabetes. Advances in Traditional Medicine 2024; doi: 10.1007/s13596-024-00774-x
|
| 104 |
Abdullah Algaissi, Anurodh S Agrawal, Song Han, Bi-Hung Peng, Chuming Luo, Fang Li, Teh-Sheng Chan, Robert B Couch, Chien-Te K Tseng. Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease. The Journal of Infectious Diseases 2019; 219(5): 829 doi: 10.1093/infdis/jiy574
|
| 105 |
Yan-Jun Dong, Li-Juan Liu, Hui-Ming Chen, Jing Sun, Ming-Hua Xiao, Jin-Hui Wu. Influence of nutritional intervention on children with type 1 diabetes mellitus and DPP-4 in serum. Experimental and Therapeutic Medicine 2017; 14(2): 913 doi: 10.3892/etm.2017.4575
|
| 106 |
Hui-Chun Huang, Shao-Jung Hsu, Chiao-Lin Chuang, Shao-Yu Hsiung, Ching-Chih Chang, Ming-Chih Hou, Fa-Yauh Lee. Effects of dipeptidyl peptidase-4 inhibition on portal hypertensive and cirrhotic rats. Journal of the Chinese Medical Association 2021; 84(12): 1092 doi: 10.1097/JCMA.0000000000000636
|
| 107 |
Fu-Shun Yen, James Cheng-Chung Wei, Hei-Tung Yip, Chii-Min Hwu, Ming-Chih Hou, Chih-Cheng Hsu. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan. Hepatology International 2021; 15(1): 179 doi: 10.1007/s12072-020-10122-1
|
| 108 |
Titli Nargis, Krishna Kumar, Amrit Raj Ghosh, Amit Sharma, Dipayan Rudra, Debrup Sen, Saikat Chakrabarti, Satinath Mukhopadhyay, Dipyaman Ganguly, Partha Chakrabarti. KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. Molecular Metabolism 2017; 6(11): 1529 doi: 10.1016/j.molmet.2017.09.004
|
| 109 |
Olga A. Smirnova, Olga N. Ivanova, Irina T. Fedyakina, Gaukhar M. Yusubalieva, Vladimir P. Baklaushev, Dmitry V. Yanvarev, Olga I. Kechko, Vladimir A. Mitkevich, Pavel O. Vorobyev, Vyacheslav S. Fedorov, Birke Bartosch, Vladimir T. Valuev-Elliston, Anastasiya L. Lipatova, Alexander V. Ivanov. SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. Cancers 2023; 15(3): 632 doi: 10.3390/cancers15030632
|
| 110 |
Leyre Martínez-Fernández, Miguel Burgos, Neira Sáinz, Laura M. Laiglesia, José Miguel Arbones-Mainar, Pedro González-Muniesa, María J. Moreno-Aliaga. Maresin 1 Exerts a Tissue-Specific Regulation of Adipo-Hepato-Myokines in Diet-Induced Obese Mice and Modulates Adipokine Expression in Cultured Human Adipocytes in Basal and Inflammatory Conditions. Biomolecules 2023; 13(6): 919 doi: 10.3390/biom13060919
|
| 111 |
Raman Sharma, Thomas S. McDonald, Heather Eng, Chris Limberakis, Benjamin D. Stevens, Sheena Patel, Amit S. Kalgutkar. In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)–Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes. Drug Metabolism and Disposition 2013; 41(12): 2148 doi: 10.1124/dmd.113.054254
|
| 112 |
Christian Baumeier, Luisa Schlüter, Sophie Saussenthaler, Thomas Laeger, Maria Rödiger, Stella Amelie Alaze, Louise Fritsche, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche, Robert Wolfgang Schwenk, Annette Schürmann. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Molecular Metabolism 2017; 6(10): 1254 doi: 10.1016/j.molmet.2017.07.016
|
| 113 |
N. V. Bulushova, I. A. Zalunin, A. S. Asrarkulova, D. G. Kozlov. Incretin Analogues in the Therapy of Type 2 Diabetes and Obesity. Applied Biochemistry and Microbiology 2022; 58(7): 854 doi: 10.1134/S0003683822070031
|
| 114 |
André J. Scheen. Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 2014; 53(9): 773 doi: 10.1007/s40262-014-0157-y
|
| 115 |
Shatadal Ghosh, Bhawna Pandey, Parames C. Sil. Pathophysiological Aspects of Proteases. 2017; : 515 doi: 10.1007/978-981-10-6141-7_20
|
| 116 |
Taras S. Panevin, Olga V. Zhelyabina, Maxim S. Eliseev, Marina V. Shestakova. Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Diabetes mellitus 2020; 23(4): 349 doi: 10.14341/DM12412
|
| 117 |
Silvano Fasolato, Elisabetta Trevellin, Mariagrazia Ruvoletto, Marnie Granzotto, Giacomo Zanus, Elisa Boscaro, Enrico Babetto, Liliana Terrin, Maria Alberta Battocchio, Francesco Ciscato, Cristian Turato, Santina Quarta, Umberto Cillo, Patrizia Pontisso, Roberto Vettor. SerpinB3 induces dipeptidyl-peptidase IV/CD26 expression and its metabolic effects in hepatocellular carcinoma. Life Sciences 2018; 200: 134 doi: 10.1016/j.lfs.2018.03.014
|
| 118 |
Jingbo Hu, Chunlin Yang, Hongbo Wang, Jing Li, Xueying Tan, Jinhui Wang, Bin Zhang, Yufen Zhao. An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 2019; 20(14): 1679 doi: 10.1080/14656566.2019.1645124
|
| 119 |
Maha H. Sharawy, Dalia H. El-Kashef, Ahmed A. Shaaban, Dina S. El-Agamy. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition. International Immunopharmacology 2021; 100: 108088 doi: 10.1016/j.intimp.2021.108088
|
| 120 |
Jaskamal Padda, Khizer Khalid, Anwar Khedr, Fahriba Tasnim, Ola A Al-Ewaidat, Ayden Charlene Cooper, Gutteridge Jean-Charles. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021; doi: 10.7759/cureus.17321
|
| 121 |
Fu-Shun Yen, Chih-Cheng Hsu, James Cheng-Chung Wei, Ming-Chih Hou, Chii-Min Hwu. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.839456
|
| 122 |
Tolulope Eniola Omolekulo, Olugbenga Samuel Michael, Lawrence Aderemi Olatunji. Sodium acetate improves disrupted glucoregulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities. Naunyn-Schmiedeberg's Archives of Pharmacology 2019; 392(1): 103 doi: 10.1007/s00210-018-1569-2
|
| 123 |
Helena H. Chowdhury, Jelena Velebit, Nataša Radić, Vito Frančič, Marko Kreft, Robert Zorec. Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes. Journal of Diabetes Research 2016; 2016: 1 doi: 10.1155/2016/7481470
|
| 124 |
Titli Nargis, Partha Chakrabarti. Significance of circulatory DPP4 activity in metabolic diseases. IUBMB Life 2018; 70(2): 112 doi: 10.1002/iub.1709
|
| 125 |
Keizo Kanasaki, Emi Kawakita, Daisuke Koya. Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00476
|
| 126 |
Takumi Kawaguchi, Takuji Torimura. Impact of insulin resistance on hepatocellular carcinoma. Kanzo 2015; 56(4): 127 doi: 10.2957/kanzo.56.127
|
| 127 |
Natasha A Trzaskalski, Evgenia Fadzeyeva, Erin E Mulvihill. Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. Clinical Medicine Insights: Endocrinology and Diabetes 2020; 13: 117955142091297 doi: 10.1177/1179551420912972
|
| 128 |
Heba M. Eltahir, Hossein M. Elbadawy, Mohannad A. Almikhlafi, Ali M. Alalawi, Ahmed J. Aldhafiri, Yaser M. Alahmadi, Sultan S. Al thagfan, Muayad Albadrani, Saber M Eweda, Mekky M. Abouzied. Sitagliptin ameliorates L-arginine-induced acute pancreatitis via modulating inflammatory cytokines expression and combating oxidative stress. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1389670
|
| 129 |
Anna Licata, Giuseppina T. Russo, Annalisa Giandalia, Marcella Cammilleri, Clelia Asero, Irene Cacciola. Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. Journal of Personalized Medicine 2023; 13(3): 558 doi: 10.3390/jpm13030558
|
| 130 |
Xin Huang, Yimin Khoong, Chengyao Han, Dai Su, Hao Ma, Shuchen Gu, Qingfeng Li, Tao Zan. Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.694605
|
| 131 |
Margaret F. Bassendine, Simon H. Bridge, Geoffrey W. McCaughan, Mark D. Gorrell. COVID‐19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?. Journal of Diabetes 2020; 12(9): 649 doi: 10.1111/1753-0407.13052
|
| 132 |
Rania M. Abdelsalam, Marwa M. Safar. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE‐NFκB and Nrf2‐antioxidant signaling pathways. Journal of Neurochemistry 2015; 133(5): 700 doi: 10.1111/jnc.13087
|
| 133 |
Diego García-Compeán, José Alberto González-González, Fernando Javier Lavalle-González, Emmanuel Irineo González-Moreno, Jesús Zacarías Villarreal-Pérez, Héctor J. Maldonado-Garza. Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Digestive Diseases and Sciences 2016; 61(2): 371 doi: 10.1007/s10620-015-3907-2
|
| 134 |
TAKUMI KAWAGUCHI, MINORU ITOU, EITARO TANIGUCHI, MICHIO SATA. Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and Δ-5-desaturase index in a murine model of non-alcoholic steatohepatitis. International Journal of Molecular Medicine 2014; 34(3): 782 doi: 10.3892/ijmm.2014.1826
|
| 135 |
Alaaeldin A. Dawood, Yasser El Ghobashy, Ayman A. Elgamal. The relationship between serum dipeptidyl peptidase-4 enzyme and nonalcoholic fatty liver disease in diabetic and nondiabetic patients. The Egyptian Journal of Internal Medicine 2018; 30(2): 49 doi: 10.4103/ejim.ejim_34_17
|
| 136 |
N.V. Bulushova, I.A. Zalunin, A.S. Asrarkulova, D.G. Kozlov. Incretin Analogues in Therapy of Type 2 Diabetes and Obesity. Biotekhnologiya 2021; 37(3): 53 doi: 10.21519/0234-2758-2021-37-3-53-64
|
| 137 |
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani. A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.937554
|
| 138 |
Manisha Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives. Life Sciences 2024; 353: 122934 doi: 10.1016/j.lfs.2024.122934
|
| 139 |
Tianpeng Zheng, Bo Chen, Liuxue Yang, Xueping Hu, Xiaoxi Zhang, Hongbo Liu, Linyuan Qin. Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population. Metabolism 2017; 73: 125 doi: 10.1016/j.metabol.2017.04.012
|
| 140 |
Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis. Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801. Current Medical Research and Opinion 2017; 33(12): 2261 doi: 10.1080/03007995.2017.1333955
|
| 141 |
S. Gentile, G. Guarino, F. Strollo, M. Romano, S. Genovese, M. Masarone, A. Ceriello. Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2016; 113: 179 doi: 10.1016/j.diabres.2015.12.006
|
| 142 |
Monika Rau, Johannes Schmitt, Thomas Berg, Andreas E. Kremer, Bruno Stieger, Katharina Spanaus, Bertram Bengsch, Marta R. Romero, Jose J. Marin, Verena Keitel, Hartwig Klinker, Hans-Peter Tony, Beat Müllhaupt, Andreas Geier, Gianfranco D. Alpini. Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. PLOS ONE 2018; 13(12): e0208225 doi: 10.1371/journal.pone.0208225
|